Since 2006, the Mesothelioma Center has raised awareness for asbestos exposure & helped thousands of families find treatment & compensation.
Mesothelioma has 4 stages that doctors use to determine cancer progression. Learn about your treatment options and prognosis at each stage.
Now, the deadly mineral is known as a proven cause of mesothelioma. Those exposed to asbestos in the workplace are at risk of getting sick decades after the fact. Learn more about asbestos exposure in the workplace below.Fact-Checked and Updated by: Laura Wright Last updated: September 9,...
The Tetraspanins (Tspan) protein family, also known as the tetraspanin family, contains 33 family members that interact with other protein molecules such as integrins, adhesion molecules, and T cell receptors by forming dimers or heterodimers. The Tspan
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, that speci
Maus et al.154reported on four individuals treated with autologous T cells electroporated with mRNA encoding a CAR derived from a murine antibody specific to human mesothelioma. One of the treated individuals experienced anaphylaxis and cardiac arrest within minutes after the third infusion, which th...
As an evolutionarily conserved signalling network, the Hippo pathway plays a crucial role in the regulation of numerous biological processes. Thus, substantial efforts have been made to understand the upstream signals that influence the activity of the H
(TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies’...
(PFS: 3 months vs 1.85 months; OS: 9.4 months vs 5.6 months) [157], suggesting this treatment combination may be a non-toxic way of improving the prognosis of patients with advanced NSCLC. Except for one case of grade 3 diarrhea in the active arm (49 patients), the overall...